Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib in previously treated Ph+ CML (BYOND)
NCT02228382Phase 4Terminated
- Sponsor
- Pfizer
- Start
- Nov 2014
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 4 trial of bosutinib in chronic myeloid leukemia (CML), sponsored by Pfizer. Started Nov 2014; status: terminated.
02
Drugs
bosutinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02228382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228382.